USFDA to review Glenmark Pharma’s NDA for Ryaltris

08 Aug 2018 Evaluate

US Food & Drug Administration (USFDA) has accepted to review the New Drug Application (NDA) of Glenmark Pharmaceuticals’ leading respiratory pipeline candidate Ryaltris, an investigational fixed-dose combination nasal spray of an antihistamine and a steroid, as a treatment for seasonal allergic rhinitis (SAR) in patients 12 years of age and older.

Ryaltris (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg]), formerly GSP 301 Nasal Spray, has been conditionally accepted by the FDA as the brand name. The filing for Ryaltris includes efficacy and safety results from two pivotal, randomized, multicenter, double-blind, placebo-controlled trials in adults and adolescents 12 years of age and older with SAR.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2002.80 -8.70 (-0.43%)
16-Jan-2026 09:42 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.95
Dr. Reddys Lab 1187.40
Cipla 1382.40
Zydus Lifesciences 881.65
Lupin 2210.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×